NCT00636558View on ClinicalTrials.gov

Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04)

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

January 12, 2012

Study Completion Date

January 12, 2012

Conditions
MelanomaBreast CancerProstate Cancer
Interventions
DRUG

CVA21

IV infusion, dose escalation of one or two infusions of escalating strength

Trial Locations (2)

2217

Cancer Care Centre, St George Hospital, Kogarah

4020

Redcliffe Hospital, Redcliffe

Sponsors

Lead Sponsor

Viralytics
All Listed Sponsors
lead

Viralytics

INDUSTRY

NCT00636558 - Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04) | Biotech Hunter | Biotech Hunter